XML 72 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8
Investment in Joint Ventures (Details Textual) (USD $)
Share data in Millions, except Per Share data, unless otherwise specified
 3 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended
Dec. 31, 2013
Dec. 31, 2013
Instruments
Products
Dec. 31, 2012
Mar. 31, 2013
Dec. 31, 2013
Private Placement
Dec. 31, 2013
Operations
Dec. 31, 2012
Operations
Dec. 31, 2013
Suspended losses
Dec. 31, 2013
PRC
Jul. 31, 2013
Medical Joint Venture
Dec. 31, 2013
Medical Joint Venture
Dec. 31, 2012
Medical Joint Venture
Dec. 31, 2013
Education Joint Venture
Mar. 31, 2013
Education Joint Venture
Dec. 31, 2013
Milestone Company
Dec. 31, 2013
Milestone Company
Food And Drug Administration
Investment in Medical Joint Venture (Textual) [Abstract]                                
Joint venture owned by the entity                 50.00%         50.00% 50.00%  
Contribution of Milestone in joint venture                 $ 1,500,000           $ 245,000 $ 225,979
Capital contribution                 1,500,000              
Instrument inception period   30 months                            
Contingency associated with the return of capital to Beijing 3H 0 0                            
Number of development of products for medical joint venture   2                            
Number of development of instruments   2                            
Loss on Earnings from Medical Joint Venture   (924,363) (171,016)     (509,803) (586,077) (414,561)                
Percentage of loss on medical joint venture 50.00% 50.00%                            
Total expenses incurred on joint venture                 2,400,000         50,000    
Investment to medical joint venture 924,115 924,115                            
Investment in medical joint venture as shared services expenditures                   336,000            
Reimbursable expenses                     260,000          
Reimbursable expense included in account receivable, net                     24,086          
Sale of stock, number of shares         2                      
Sale of stock, price per share         $ 1.50                      
Sale of stock, value         3,000,000                      
Net proceeds received in joint venture 2,363,000                              
Percentage of ownership before transaction 50.00%                              
Percentage of ownership after transaction 45.50%                              
Gain on dilution effect 1,363,650                              
Loss incurred by joint ventures                     1,019,606 1,172,154 (15,836)      
Loan from parent company CEO       $ 50,000